The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and is likely the result of the development process of these drugs in which selectivity for Cdk4 over Cdk2 was prioritized38,39.”
From Allostery governs Cdk2 activation and differential recognition of CDK inhibitors (2021) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Research works printed but not linked: 86
- Hanahan D., 2000, Cell, 100, 70, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- Malumbres M., 2001, Nat. Rev. Cancer, 1, 231, 10.1038/35106065 · DOI · Paper page
- Morgan D. O., 1997, Annu. Rev. Cell. Dev. Biol., 13, 291, 10.1146/annurev.cellbio.13.1.261 · DOI · Paper page
- Sherr C. J., 1999, Genes Dev., 13, 1512, 10.1101/gad.13.12.1501 · DOI · Paper page
- Fry D. W., 2000, Curr. Opin. Oncologic, Endocrine Metab. Invest. Drugs., 2, 59
- Garrett M. D., 1999, Curr. Opin. Genet. Dev., 9, 111, 10.1016/S0959-437X(99)80015-X · DOI
- Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
- Huwe A., 2003, Angew. Chem. Int. Ed., 42, 2138, 10.1002/anie.200200540 · DOI · Paper page
- Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
- Rosania G. R., 2000, Exp. Opin. Ther. Pat., 10, 230, 10.1517/13543776.10.2.215 · DOI
- Webster K. R., 2000, Emerging Drugs, 5, 59, 10.1517/14728214.5.1.45 · DOI
- Sielecki T. M., 2000, J. Med. Chem., 43, 18, 10.1021/jm990256j · DOI · Paper page
- Mani S., 2000, Exp. Opin. Invest. Drugs, 9, 1870, 10.1517/13543784.9.8.1849 · DOI
- Meijer L, 2003, Acc. Chem. Res., 36, 425, 10.1021/ar0201198 · doi:10.1021/ar0201198
- Davies T. G., 2002, Nat. Struct. Biol., 9, 749, 10.1038/nsb842 · DOI · Paper page
- Dreyer M. K., 2001, J. Med. Chem., 44, 530, 10.1021/jm001043t · DOI
- Legraverend M., 2000, J. Med. Chem., 43, 1292, 10.1021/jm9911130 · DOI
- Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
- Chang Y.-T., 1999, Chem. Biol., 6, 375
- Imbach P., 1999, Bioorg. Med. Chem. Lett., 9, 96, 10.1016/S0960-894X(98)00691-X · DOI
- Gray N. S., 1998, Science, 281, 538, 10.1126/science.281.5376.538 · DOI · Paper page
- Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
- Brooks E. E., 1997, J. Biol. Chem., 272, 29211, 10.1074/jbc.272.46.29207 · DOI
- Havlíček L., 1997, J. Med. Chem., 40, 412, 10.1021/jm960666x · DOI · Paper page
- Meijer L., 1997, Eur. J. Biochem., 243, 536, 10.1111/j.1432-1033.1997.t01-2-00527.x · DOI · Paper page
- Veselý J., 1994, Eur. J. Biochem., 224, 786, 10.1111/j.1432-1033.1994.00771.x · DOI · Paper page
- McClue S. J., 2002, Int. J. Cancer, 102, 468, 10.1002/ijc.10738 · DOI · Paper page
- Zaharevitz D. W., 1999, Cancer Res., 59, 2569
- Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Schultz C., 1999, J. Med. Chem., 42, 2919, 10.1021/jm9900570 · DOI · Paper page
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Sayle K. L., 2003, Bioorg. Med. Chem. Lett., 13, 3082, 10.1016/S0960-894X(03)00651-6 · DOI
- Anderson M., 2003, Bioorg. Med. Chem. Lett., 13, 3026, 10.1016/S0960-894X(03)00638-3 · DOI
- Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
- Mesguiche V., 2003, Bioorg. Med. Chem. Lett., 13, 222, 10.1016/S0960-894X(02)00884-3 · DOI
- Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
- Kim K. S., 2002, J. Med. Chem., 45, 3927
- Ortega M. A., 2002, Bioorg. Med. Chem. Lett., 10, 2184, 10.1016/S0968-0896(02)00069-X · DOI
- Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
- Davis S. T., 2001, Science, 291, 137, 10.1126/science.291.5501.134 · DOI · Paper page
- Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
- Furet P., 2001, J. Comput.-Aided Mol. Des., 15, 495, 10.1023/A:1011128510728 · DOI
- Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
- Seong Y.-S., 2003, Cancer Res., 63, 7391
- Murthi K. K., 2000, Bioorg. Med. Chem. Lett., 10, 1041, 10.1016/S0960-894X(00)00156-6 · DOI
- Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
- Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
- Bramson H. N., 2001, J. Med. Chem., 44, 4358, 10.1021/jm010117d · DOI · Paper page
- Yue E. W., 2002, J. Med. Chem., 45, 5248
- Nugiel D. A., 2002, J. Med. Chem., 45, 5232, 10.1021/jm020171+ · DOI
- Nugiel D. A., 2001, J. Med. Chem., 44, 1336, 10.1021/jm0100032 · DOI
- Lane M. E., 2001, Cancer Res., 61, 6177
- Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
- Honma T., 2001, J. Med. Chem., 44, 4627
- Honma T., 2001, J. Med. Chem., 44, 4640
- Soni R., 2001, J. Natl. Cancer Inst., 93, 446, 10.1093/jnci/93.6.436 · DOI
- Beattie J. F., 2003, Bioorg. Med. Chem. Lett., 13, 2960, 10.1016/S0960-894X(03)00202-6 · DOI
- Breault G. A., 2003, Bioorg. Med. Chem. Lett., 13, 2966, 10.1016/S0960-894X(03)00203-8 · DOI
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
- Engler T. A., 2003, Bioorg. Med. Chem. Lett., 13, 2267, 10.1016/S0960-894X(03)00461-X · DOI
- Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
- Zhu G., 2003, J. Med. Chem., 46, 2030
- Carini D. J., 2001, Bioorg. Med. Chem. Lett., 11, 2211, 10.1016/S0960-894X(01)00416-4 · DOI
- Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
- Soni R., 2000, Biochem. Biophys. Res. Commun., 275, 884, 10.1006/bbrc.2000.3349 · DOI · Paper page
- Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
- Murthi K. K., 2000, Bioorg. Med. Chem. Lett., 10, 1041, 10.1016/S0960-894X(00)00156-6 · DOI
- Kim K. S., 2000, J. Med Chem., 43, 4134
- Hoessel R., 1999, Nat. Cell Biol., 1, 67, 10.1038/9035 · DOI · Paper page
- Meijer L., 2000, Chem. Biol., 7, 63, 10.1016/S1074-5521(00)00063-6 · DOI · Paper page
- DePinto W. E., 2003, American Association of Cancer Research 95th Annual National Meeting, Mar 27−31
- Barvian M., 2000, J. Med. Chem., 43, 4616, 10.1021/jm000271k · DOI
- Fry D. W., 2001, J. Biol. Chem., 276, 16623
- Toogood P. L, 2001, Med. Res. Rev., 21, 498, 10.1002/med.1021 · DOI
- Gray N., 1999, Curr. Med. Chem., 6, 875
- Griffith W. P., 1987, J. Chem. Soc., Chem. Commun., 1625, 10.1039/c39870001625 · doi:10.1039/c39870001625
- Surya Prakash G. K., 1989, J. Am. Chem. Soc., 111, 395, 10.1021/ja00183a074 · DOI
- Walter M. W., 1998, Org. Chem., 63, 5192, 10.1021/jo980443+ · doi:10.1021/jo980443+
- Dess D. B., 1983, J. Org. Chem., 48, 4156, 10.1021/jo00170a071 · doi:10.1021/jo00170a071
- Davis F. A., 1982, J. Org. Chem., 47, 1775, 10.1021/jo00348a040 · doi:10.1021/jo00348a040
- Davis F. A., 1982, J. Am. Chem. Soc., 104, 5418
- Toodgood P. L., 2005, J. Med. Chem., 48, 2406
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Self-citationCyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Metadata
- Authors
- VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., & Toogood, P. L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-02
- Volume
- 48
- Issue
- 7
- Pages
- 2371-2387
- ISSN
- 0022-2623
- 1520-4804
- Cited by
- 119
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4. https://app.cochat.ai/papers/10.1021/jm049355+
- The paper
- VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., & Toogood, P. L. (2005). Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm049355%2B
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.